RAD51 and hepatocellular carcinoma: In our study, the data suggested that RAD51 was upregulated in HCC, RAD51 silencing or inhibition exhibits antitumor activity toward HCC, and RAD51 inhibition has a synergistic inhibitory effect with sorafenib.